Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Gilles Salles, MD PhD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Daniel James Hodson, MD PhD, Krimo Bouabdallah, MD, Loic Ysebaert, MD PhD, Guillaume Cartron, Andrew John Davies, PhD, Alexey V Danilov, MD PhD, Christopher Fegan, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Franck Morschhauser, MD

Blood (2018) 132 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2018-99-113115

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Franck Morschhauser, MD, John Radford, MD FRCP, Loic Ysebaert, MD PhD, Stephen E Spurgeon, MD, Ebenezer A Kio, MD, Gilles Salles, MD PhD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Simon Rule, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath

Blood (2018) 132 (Supplement 1): 5345.

https://doi.org/10.1182/blood-2018-99-113117

Published: 2018

Journal Articles

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Alexey V Danilov, MD PhD, Charles Herbaux, MD, Martin J.S. Dyer, MA, DPhil, FRCP, FRCPath, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, Simon Rule, MD, Ebenezer A Kio, MD, Xi Huang, PhD, Siddhartha Mitra, MD PhD, Lionel Karlin, MD, Christopher Fegan, MD

Blood (2018) 132 (Supplement 1): 3135.

https://doi.org/10.1182/blood-2018-99-113111

Published: 2018

Journal Articles

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Michael B Tomblyn, MD, MS, Thomas E. Witzig, MD, Andrew L Himelstein, MD, Rebecca Elstrom, MD, Ebenezer A Kio, MD, Robert M Sharkey, PhD, Jonathan Rojo, MD, William Wegener, MD, PhD, David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 3680.

https://doi.org/10.1182/blood.V120.21.3680.3680

Published: 2012

Journal Articles

Increased Stability of Bcl-2 mRNA in B-Cell Chronic Lymphocytic Leukemia (CLL).

Ebenezer A. Kio, MD, Mauricio Pineda-Roman, MD, Yoko Otake, MS, Robert K. Stuart, MD, Daniel J. Fernandes, PhD, DSc

Blood (2004) 104 (11): 4789.

https://doi.org/10.1182/blood.V104.11.4789.4789

Published: 2004

NARROW

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Increased Stability of Bcl-2 mRNA in B-Cell Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Entospletinib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination with Idelalisib in Patients with B-Cell Lymphoma

Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia

Combination Therapy Targeting Two Different Antigens with Anti-CD22 Radioimmunotherapy and Anti-CD20 Immunotherapy in Non-Hodgkin Lymphoma (NHL): Phase I Results

Increased Stability of Bcl-2 mRNA in B-Cell Chronic Lymphocytic Leukemia (CLL).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only